Diabetes and Liver an Association: Hepatogenous Diabetes Mechanism and Some Evidences

Acharya, Ajita; Wudneh, Eden; Krishnan, Radhika; Ashraf, Aisha; Tohid, Hassaan

doi:10.4172/2157-7013.1000257

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes mellitus is characterized by hyperglycemia owing to either a decrease in insulin production, insulin resistance, or both 1 . It can be classified into type 1, which results from autoimmune destruction of the pancreatic beta cells, and type 2, which occurs owing to insulin resistance or deficiency 2 . The symptoms of diabetes mellitus include polyuria, polydipsia, and polyphagia.…”

Section: Introductionmentioning

confidence: 99%

“…The symptoms of diabetes mellitus include polyuria, polydipsia, and polyphagia. The liver plays an important role in carbohydrate homeostasis, where accumulation of glycogen in the liver induces liver enzyme abnormalities in uncontrolled diabetic patients 2 . Non-alcoholic fatty liver disease (NAFLD) is a common complication of diabetes, usually observed in patients with type 2 diabetes and can progress to liver cirrhosis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats

Makena

Hamman

Buraimoh

et al. 2018

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

Objectives The objective of this study was to evaluate the therapeutic effects of balanitoside in diabetic rats. Methods Twenty-five rats were divided into five groups. Rats in groups 2 to 5 were treated with streptozotocin to induce hyperglycemia. In addition, rats in groups 1 and 2 received 1 mL of distilled water, whereas those in groups 3, 4, and 5 received 10 and 20 mg/kg balanitoside and 6 U/kg insulin, respectively, for 14 days. All rats were sacrificed on day 15, blood samples were collected, and serum levels of alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were measured. The liver was processed for examination under a light microscope. Results The results showed a significant decrease in liver protein concentrations in diabetic control rats, compared to those in the normal control rats and rats treated with 10 mg/kg balanitoside ( p < 0.05). There was no significant difference in ALP levels among all groups. However, a significant increase in ALT and AST levels was observed in the diabetic control rats, compared to those in the normal control rats ( p < 0.05). Photomicrographs of the liver of the diabetic control rats showed fat and glycogen droplets, vacuolated nuclei, and loss of cellular boundaries, whereas those of the rats treated with balanitoside or insulin showed a small amount of microvesicular fat droplets and slight infiltration of lymphocytes. Conclusion The findings of this study suggest the therapeutic effects of balanitoside in the liver of diabetic rats.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Therapeutic effects of balanitoside in streptozotocin-induced diabetic rats

Makena

Hamman

Buraimoh

et al. 2018

Journal of Taibah University Medical Sciences

View full text Add to dashboard Cite

show abstract

“…Similarly, hepatogenous diabetes (HD) has been evidenced by the progression of irregular insulin clearance and β -pancreatic cell apoptosis [ 33 ]. The presence of liver disorders disrupts glucose metabolism due to insulin resistance and impaired sensitivity of pancreatic islet β -cells [ 34 , 35 ]. Initially, insulin resistance and glucose intolerance occur at the initial stage of HD; however, with its progression, the manifestation of diabetic symptoms becomes clinically distinct.…”

Section: Pathophysiology Of Hepatic Disorders and Dmmentioning

confidence: 99%

Reenvisioning Traditional to Regenerative Therapeutic Advances in Managing Nonalcoholic Fatty Liver Disease in Diabetes Mellitus

Tsai

Dubey

et al. 2021

Journal of Diabetes Research

View full text Add to dashboard Cite

Reports indicate the increasing prevalence of liver disorders in diabetes mellitus (DM) patients. Clinically, it has also been revealed that the existence of nonalcoholic fatty liver disease (NAFLD) enhances the incidence of type 2 diabetes mellitus (T2DM), while T2DM exacerbates NAFLD to extremely severe forms of steatohepatitis, cirrhosis, and hepatocellular carcinoma. This implies the coexistence and bidirectional nature of NAFLD and T2DM, which function synergistically to drive adverse consequences in clinical practice. For treatment of such comorbid state, though the existing practices such as lifestyle management, traditional Chinese medicines (TCM), and pharmaceuticals have offered somewhat relief, the debate continues about the optimal therapeutic impacts. Recent developments in the field of tissue engineering have led to a renewed interest in novel biomaterial alternatives such as stem cells. This might be attributable to their differentiation potential towards hepatic and pancreatic lineage. These cellular therapies could be further complemented by platelet-derived biomaterials, TCM formulations, or any specific drug. Based on these abovementioned approaches, we aimed to comprehensively analyze various preclinical and clinical studies from traditional to regenerative therapeutic approaches in managing concomitant NAFLD and T2DM.

show abstract